Philip A. Thompson
Mary Baldwin University(US)The Royal Melbourne Hospital(AU)Mayo Clinic(US)The University of Texas MD Anderson Cancer Center(US)The University of Texas MD Anderson Cancer Center(US)The University of Melbourne(AU)University of Melbourne(AU)Peter MacCallum Cancer Centre(AU)Düsseldorf University Hospital(DE)Integrated Oncology (United States)(US)Mayo Clinic in Arizona(US)Mayo Clinic Hospital(US)University Hospital Cologne(DE)Heinrich Heine University Düsseldorf(DE)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Immunodeficiency and Autoimmune Disorders, Acute Lymphoblastic Leukemia research
Most-Cited Works
- → Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors(2020)2,047 cited
- → Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia(2015)500 cited
- → Ibrutinib and Venetoclax for First-Line Treatment of CLL(2019)495 cited
- → Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies(2019)352 cited
- → 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial(2020)327 cited
- → Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens(2015)247 cited